Role of Innate Immune and Inflammatory Responses in the
Development of Secondary Diabetic Complications

Trevor   J.   Plowman; Mujtaba   H.   Shah; Emely      Fernandez; Hannah      Christensen; Myia      Aiges; Kota   V.   Ramana
doi:10.2174/1566524023666220922114701
Abstract

Increased hyperglycemia due to uncontrolled diabetes is the major cause of secondary diabetic complications such as retinopathy, neuropathy, nephropathy, and cardiovascular diseases. Although it is well known that increased oxidative stress, activation of the polyol pathway, protein kinase C and increased generation of advanced glycation end products could contribute to the development of diabetic complications, recent studies implicated the role of innate immunity and its related inflammatory responses in the pathophysiology of secondary diabetic complications. Increased activation of oxidative stress signaling could regulate NLRP3 inflammasome-mediated innate immune responses as well as NF-κB signalosome-mediated pro-inflammatory responses. This review article focused on the pathogenic role of innate immune and inflammatory responses in the progression of hyperglycemia-induced secondary diabetic complications. Specifically, we discussed in depth how deregulated innate immune and inflammatory responses could lead to an aggravated release of cytokines, chemokines, and growth factors resulting in the development of various secondary complications of diabetes.
Keywords: Diabetes, hyperglycemia, innate immunity, inflammation, oxidative stress, glucose.
« Previous Next »
[1]
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis  2018; 25(2): 121-32.
 [http://dx.doi.org/10.1053/j.ackd.2017.10.011] [PMID: 29580576]

[2]
Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science  2005; 307(5708): 380-4.
 [http://dx.doi.org/10.1126/science.1104345] [PMID: 15662003]

[3]
Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes  2005; 54(S2): S32-9.
 [http://dx.doi.org/10.2337/diabetes.54.suppl_2.S32] [PMID: 16306337]

[4]
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes  2008; 26(2): 77-82.
 [http://dx.doi.org/10.2337/diaclin.26.2.77]

[5]
Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature  2000; 404(6779): 787-90.
 [http://dx.doi.org/10.1038/35008121] [PMID: 10783895]

[6]
Nishikawa T, Edelstein D, Brownlee M. The missing link: A single unifying mechanism for diabetic complications. Kidney Int  2000; 58: S26-30.
 [http://dx.doi.org/10.1046/j.1523-1755.2000.07705.x] [PMID: 10997687]

[7]
Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal  2007; 9(3): 343-53.
 [http://dx.doi.org/10.1089/ars.2006.1458] [PMID: 17184177]

[8]
Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med  2003; 9(3): 294-9.
 [http://dx.doi.org/10.1038/nm834] [PMID: 12592403]

[9]
Bönhof GJ, Sipola G, Strom A, et al. BOND study: A randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open  2022; 12(2): e057142.
 [http://dx.doi.org/10.1136/bmjopen-2021-057142] [PMID: 35115359]

[10]
Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev  2005; 26(3): 380-92.
 [http://dx.doi.org/10.1210/er.2004-0028] [PMID: 15814847]

[11]
Wu XQ, Zhang DD, Wang YN, Tan YQ, Yu XY, Zhao YY. AGE/RAGE in diabetic kidney disease and ageing kidney. Free Radic Biol Med  2021; 171: 260-71.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2021.05.025] [PMID: 34019934]

[12]
Sanajou D, Ghorbani HA, Argani H, Aslani S. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. Eur J Pharmacol  2018; 833: 158-64.
 [http://dx.doi.org/10.1016/j.ejphar.2018.06.001] [PMID: 29883668]

[13]
Kolczynska K, Loza-Valdes A, Hawro I, Sumara G. Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: A review. Lipids Health Dis  2020; 19(1): 113.
 [http://dx.doi.org/10.1186/s12944-020-01286-8] [PMID: 32466765]

[14]
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res  2010; 106(8): 1319-31.
 [http://dx.doi.org/10.1161/CIRCRESAHA.110.217117] [PMID: 20431074]

[15]
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol  2020; 37: 101799.
 [http://dx.doi.org/10.1016/j.redox.2020.101799] [PMID: 33248932]

[16]
Elumalai S, Karunakaran U, Moon JS, Won KC. NADPH oxidase (NOX) targeting in diabetes: A special emphasis on pancreatic β-cell dysfunction. Cells  2021; 10(7): 1573.
 [http://dx.doi.org/10.3390/cells10071573] [PMID: 34206537]

[17]
Moscat J, Diaz-Meco MT, Rennert P. NF‐κB activation by protein kinase C isoforms and B‐cell function. EMBO Rep  2003; 4(1): 31-6.
 [http://dx.doi.org/10.1038/sj.embor.embor704] [PMID: 12524517]

[18]
Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes  2004; 53(11): 2910-20.
 [http://dx.doi.org/10.2337/diabetes.53.11.2910] [PMID: 15504972]

[19]
Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest  2001; 108(9): 1341-8.
 [http://dx.doi.org/10.1172/JCI11235] [PMID: 11696579]

[20]
Daniels MC, McClain DA, Crook ED. Transcriptional regulation of transforming growth factor β1 by glucose: Investigation into the role of the hexosamine biosynthesis pathway. Am J Med Sci  2020; 359(2): 79-83.
 [http://dx.doi.org/10.1016/j.amjms.2019.12.013] [PMID: 32039769]

[21]
Patel S, Santani D. Role of NF-κB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep  2009; 61(4): 595-603.
 [http://dx.doi.org/10.1016/S1734-1140(09)70111-2] [PMID: 19815941]

[22]
Bai Y, Mu Q, Bao X, et al. Targeting NLRP3 inflammasome in the treatment of diabetes and diabetic complications: Role of natural compounds from herbal medicine. Aging Dis  2021; 12(7): 1587-604.
 [http://dx.doi.org/10.14336/AD.2021.0318] [PMID: 34631209]

[23]
Wang Z, Ni X, Zhang L, et al. Toll-like receptor 4 and inflammatory micro-environment of pancreatic islets in type-2 diabetes mellitus: A therapeutic perspective. Diabetes Metab Syndr Obes  2020; 13: 4261-72.
 [http://dx.doi.org/10.2147/DMSO.S279104] [PMID: 33204132]

[24]
Jin X, Zhou R, Huang Y. Role of inflammasomes in HIV-1 infection and treatment. Trends Mol Med  2022; S1471-4914(22): 51.
 [http://dx.doi.org/10.1016/j.molmed.2022.02.010]

[25]
Gomes CP, Torloni MR, Gueuvoghlanian-Silva BY, Alexandre SM, Mattar R, Daher S. Cytokine levels in gestational diabetes mellitus: A systematic review of the literature. Am J Reprod Immunol  2013; 69(6): n/a.
 [http://dx.doi.org/10.1111/aji.12088] [PMID: 23414425]

[26]
Sabaner MC, Akdogan M, Doğan M, et al. Inflammatory cytokines, oxidative and antioxidative stress levels in patients with diabetic macular edema and hyperreflective spots. Eur J Ophthalmol  2021; 31(5): 2535-45.
 [http://dx.doi.org/10.1177/1120672120962054] [PMID: 33008266]

[27]
Khan S, Luck H, Winer S, Winer DA. Emerging concepts in intestinal immune control of obesity-related metabolic disease. Nat Commun  2021; 12(1): 2598.
 [http://dx.doi.org/10.1038/s41467-021-22727-7] [PMID: 33972511]

[28]
Zhuang Y, Zhang J, Li Y, et al. B lymphocytes are predictors of insulin resistance in women with gestational diabetes mellitus. Endocr Metab Immune Disord Drug Targets  2019; 19(3): 358-66.
 [http://dx.doi.org/10.2174/1871530319666190101130300] [PMID: 30621567]

[29]
Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res  2017; 139: 7-14.
 [http://dx.doi.org/10.1016/j.visres.2017.04.003] [PMID: 28412095]

[30]
Xu HZ, Le YZ. Significance of outer blood-retina barrier breakdown in diabetes and ischemia. Invest Ophthalmol Vis Sci  2011; 52(5): 2160-4.
 [http://dx.doi.org/10.1167/iovs.10-6518] [PMID: 21178141]

[31]
Simó R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: Does it really matter? Diabetologia  2018; 61(9): 1902-12.
 [http://dx.doi.org/10.1007/s00125-018-4692-1] [PMID: 30030554]

[32]
Chen M, Curtis TM, Stitt AW. Advanced glycation end products and diabetic retinopathy. Curr Med Chem  2013; 20(26): 3234-40.
 [http://dx.doi.org/10.2174/09298673113209990025] [PMID: 23745547]

[33]
Forrester JV, Xu H. Good news–bad news: the yin and yang of immune privilege in the eye. Front Immunol  2012; 3: 338.
 [http://dx.doi.org/10.3389/fimmu.2012.00338] [PMID: 23230433]

[34]
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet  2010; 376(9735): 124-36.
 [http://dx.doi.org/10.1016/S0140-6736(09)62124-3] [PMID: 20580421]

[35]
Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Prog Retin Eye Res  2010; 29(2): 95-112.
 [http://dx.doi.org/10.1016/j.preteyeres.2009.11.003] [PMID: 19961953]

[36]
Muramatsu D, Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Goto H. Correlation of complement fragment C5a with inflammatory cytokines in the vitreous of patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol  2013; 251(1): 15-7.
 [http://dx.doi.org/10.1007/s00417-012-2024-6] [PMID: 22527328]

[37]
Cheng L, Bu H, Portillo JAC, et al. Modulation of retinal Müller cells by complement receptor C5aR. Invest Ophthalmol Vis Sci  2013; 54(13): 8191-8.
 [http://dx.doi.org/10.1167/iovs.13-12428] [PMID: 24265019]

[38]
Kowluru RA, Chakrabarti S, Chen S. Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-kB) in the retina. Acta Diabetol  2004; 41(4): 194-9.
 [http://dx.doi.org/10.1007/s00592-004-0165-8] [PMID: 15660203]

[39]
Chen M, Wang W, Ma J, Ye P, Wang K. High glucose induces mitochondrial dysfunction and apoptosis in human retinal pigment epithelium cells via promoting SOCS1 and Fas/FasL signaling. Cytokine  2016; 78: 94-102.
 [http://dx.doi.org/10.1016/j.cyto.2015.09.014] [PMID: 26700587]

[40]
Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol  2001; 158(1): 147-52.
 [http://dx.doi.org/10.1016/S0002-9440(10)63952-1] [PMID: 11141487]

[41]
Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications  2001; 15(5): 257-9.
 [http://dx.doi.org/10.1016/S1056-8727(01)00155-6] [PMID: 11522500]

[42]
Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One  2009; 4(12): e8158.
 [http://dx.doi.org/10.1371/journal.pone.0008158] [PMID: 19997642]

[43]
Chen H, Zhang X, Liao N, Wen F. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy. BMC Ophthalmol  2017; 17(1): 176.
 [http://dx.doi.org/10.1186/s12886-017-0572-6] [PMID: 28969616]

[44]
Harada C, Harada T, Mitamura Y, et al. Diverse NF-kappaB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy. Mol Vis  2004; 10: 31-6.
 [PMID: 14737065]

[45]
Sui A, Chen X, Shen J, et al. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model. Cell Death Dis  2020; 11(10): 901.
 [http://dx.doi.org/10.1038/s41419-020-03076-7] [PMID: 33093455]

[46]
Liu Q, Zhang F, Zhang X, et al. Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. Mol Cell Biochem  2018; 445(1-2): 105-15.
 [http://dx.doi.org/10.1007/s11010-017-3256-x] [PMID: 29264825]

[47]
Yin Y, Chen F, Wang W, Wang H, Zhang X. Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats: Possible involvement of NLRP3 inflammasome and NF-κB signaling pathway. Mol Vis  2017; 23: 242-50.
 [PMID: 28465656]

[48]
Chen W, Zhao M, Zhao S, et al. Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: A novel inhibitory effect of minocycline. Inflamm Res  2017; 66(2): 157-66.
 [http://dx.doi.org/10.1007/s00011-016-1002-6] [PMID: 27785530]

[49]
Loukovaara S, Piippo N, Kinnunen K, Hytti M, Kaarniranta K, Kauppinen A. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol  2017; 95(8): 803-8.
 [http://dx.doi.org/10.1111/aos.13427] [PMID: 28271611]

[50]
Chen H, Zhang X, Liao N, et al. Enhanced expression of NLRP3 inflammasome-related inflammation in diabetic retinopathy. Invest Ophthalmol Vis Sci  2018; 59(2): 978-85.
 [http://dx.doi.org/10.1167/iovs.17-22816] [PMID: 29450537]

[51]
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care  2005; 28(1): 164-76.
 [http://dx.doi.org/10.2337/diacare.28.1.164] [PMID: 15616252]

[52]
Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes  2014; 5(3): 393-8.
 [http://dx.doi.org/10.4239/wjd.v5.i3.393] [PMID: 24936261]

[53]
Chen HY, Zhong X, Huang XR, et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol Ther  2014; 22(4): 842-53.
 [http://dx.doi.org/10.1038/mt.2013.235] [PMID: 24445937]

[54]
Chien HY, Chen CY, Chiu YH, Lin YC, Li WC. Differential microRNA profiles predict diabetic nephropathy progression in Taiwan. Int J Med Sci  2016; 13(6): 457-65.
 [http://dx.doi.org/10.7150/ijms.15548] [PMID: 27279796]

[55]
Huang Y, Liu Y, Li L, et al. Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: Implications for glomerular endothelial injury. BMC Nephrol  2014; 15(1): 142.
 [http://dx.doi.org/10.1186/1471-2369-15-142] [PMID: 25182190]

[56]
Sanchez-Alamo B, Shabaka A, Cachofeiro V, Cases-Corona C, Fernandez-Juarez G. Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy. Clin Nephrol  2022; 97(1): 1-9.
 [http://dx.doi.org/10.5414/CN110223] [PMID: 34753557]

[57]
Fujihara CK, Antunes GR, Mattar AL, Malheiros DMAC, Vieira JM Jr, Zatz R. Chronic inhibition of nuclear factor-κB attenuates renal injury in the 5/6 renal ablation model. Am J Physiol Renal Physiol  2007; 292(1): F92-9.
 [http://dx.doi.org/10.1152/ajprenal.00184.2006] [PMID: 16896182]

[58]
Foresto-Neto O, Albino AH, Arias SCA, et al. NF-κB system is chronically activated and promotes glomerular injury in experimental type 1 diabetic kidney disease. Front Physiol  2020; 11: 84.
 [http://dx.doi.org/10.3389/fphys.2020.00084] [PMID: 32116790]

[59]
Wei M, Li Z, Xiao L, Yang Z. Effects of ROS-relative NF-κB signaling on high glucose-induced TLR4 and MCP-1 expression in podocyte injury. Mol Immunol  2015; 68(2) (2 Pt A): 261-71.
 [http://dx.doi.org/10.1016/j.molimm.2015.09.002] [PMID: 26364141]

[60]
Verzola D, Cappuccino L, D’Amato E, et al. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney Int  2014; 86(6): 1229-43.
 [http://dx.doi.org/10.1038/ki.2014.116] [PMID: 24786705]

[61]
McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. Am J Kidney Dis  2008; 52(3): 454-63.
 [http://dx.doi.org/10.1053/j.ajkd.2008.01.025] [PMID: 18433957]

[62]
Tuttle KR, Brosius FC III, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: Results from a Phase 2 randomized controlled clinical trial. Nephrol Dial Transplant  2018; 33(11): 1950-9.
 [http://dx.doi.org/10.1093/ndt/gfx377] [PMID: 29481660]

[63]
Moon JY, Jeong KH, Lee TW, Ihm CG, Lim SJ, Lee SH. Aberrant recruitment and activation of T cells in diabetic nephropathy. Am J Nephrol  2012; 35(2): 164-74.
 [http://dx.doi.org/10.1159/000334928] [PMID: 22286547]

[64]
Moriwaki Y, Yamamoto T, Shibutani Y, et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism  2003; 52(5): 605-8.
 [http://dx.doi.org/10.1053/meta.2003.50096] [PMID: 12759891]

[65]
Wu J, Raman A, Coffey NJ, et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest  2021; 131(20): e136329.
 [http://dx.doi.org/10.1172/JCI136329] [PMID: 34651582]

[66]
Xu X, Huang X, Zhang L, Huang X, Qin Z, Hua F. Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway. BMC Nephrol  2021; 22(1): 218.
 [http://dx.doi.org/10.1186/s12882-021-02391-1] [PMID: 34107901]

[67]
Chen K, Feng L, Hu W, et al. Optineurin inhibits NLRP3 inflammasome activation by enhancing mitophagy of renal tubular cells in diabetic nephropathy. FASEB J  2019; 33(3): 4571-85.
 [http://dx.doi.org/10.1096/fj.201801749RRR] [PMID: 30571313]

[68]
Ying C, Zhou Z, Dai J, et al. Activation of the NLRP3 inflammasome by RAC1 mediates a new mechanism in diabetic nephropathy. Inflamm Res  2022; 71(2): 191-204.
 [http://dx.doi.org/10.1007/s00011-021-01532-4] [PMID: 35028708]

[69]
Lu M, Yin N, Liu W, Cui X, Chen S, Wang E. Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling. BioMed Res Int  2017; 2017: 1-10.
 [http://dx.doi.org/10.1155/2017/1516985] [PMID: 28194406]

[70]
Dong W, Jia C, Li J, et al. Fisetin attenuates diabetic nephropathy-induced podocyte injury by inhibiting NLRP3 inflammasome. Front Pharmacol  2022; 13: 783706.
 [http://dx.doi.org/10.3389/fphar.2022.783706] [PMID: 35126159]

[71]
Said G. Diabetic neuropathy—a review. Nat Clin Pract Neurol  2007; 3(6): 331-40.
 [http://dx.doi.org/10.1038/ncpneuro0504] [PMID: 17549059]

[72]
Russell JW, Zilliox LA. Diabetic neuropathies. Continuum  2014; 20(5): 1226-40.
 [http://dx.doi.org/10.1212/01.CON.0000455884.29545.d2]

[73]
Lipnick JA, Lee TH. Diabetic neuropathy. Am Fam Physician  1996; 54(8): 2478-2484, 2487-2488.
 [PMID: 8961847]

[74]
Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers  2019; 5(1): 41.
 [http://dx.doi.org/10.1038/s41572-019-0092-1] [PMID: 31197153]

[75]
Albers JW, Pop-Busui R. Diabetic neuropathy: Mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep  2014; 14(8): 473.
 [http://dx.doi.org/10.1007/s11910-014-0473-5] [PMID: 24954624]

[76]
Zhou J, Zhou S. Inflammation: Therapeutic targets for diabetic neuropathy. Mol Neurobiol  2014; 49(1): 536-46.
 [http://dx.doi.org/10.1007/s12035-013-8537-0] [PMID: 23990376]

[77]
Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: Mechanisms to management. Pharmacol Ther  2008; 120(1): 1-34.
 [http://dx.doi.org/10.1016/j.pharmthera.2008.05.005] [PMID: 18616962]

[78]
Qiang X, Satoh J, Sagara M, et al. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metabolism  1998; 47(8): 977-81.
 [http://dx.doi.org/10.1016/S0026-0495(98)90354-7] [PMID: 9711995]

[79]
Santos DFS, Donahue RR, Laird DE, Oliveira MCG, Taylor BK. The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy. Neuropharmacology  2022; 205: 108907.
 [http://dx.doi.org/10.1016/j.neuropharm.2021.108907] [PMID: 34856203]

[80]
Shi X, Chen Y, Nadeem L, Xu G. Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. J Neuroinflammation  2013; 10(1): 836.
 [http://dx.doi.org/10.1186/1742-2094-10-69] [PMID: 23735240]

[81]
Chanda D, Ray S, Chakraborti D, Sen S, Mitra A. Interleukin-6 levels in patients with diabetic polyneuropathy. Cureus  2022; 14(2): e21952.
 [http://dx.doi.org/10.7759/cureus.21952] [PMID: 35155045]

[82]
Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab  2009; 94(6): 2157-63.
 [http://dx.doi.org/10.1210/jc.2008-2385] [PMID: 19276232]

[83]
Magrinelli F, Briani C, Romano M, Ruggero S, Toffanin E, Triolo G, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res  2015; 2015: 547834.
 [http://dx.doi.org/10.1155/2015/547834]

[84]
Zheng H, Sun W, Zhang Q, et al. Proinflammatory cytokines predict the incidence of diabetic peripheral neuropathy over 5 years in Chinese type 2 diabetes patients: A prospective cohort study. EClinic Med  2021; 31: 100649.
 [http://dx.doi.org/10.1016/j.eclinm.2020.100649] [PMID: 33385123]

[85]
Herder C, Kannenberg JM, Huth C, et al. Myeloperoxidase, superoxide dismutase-3, cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study. Diabetes Metab Res Rev  2018; 34(5): e3000.
 [http://dx.doi.org/10.1002/dmrr.3000] [PMID: 29577557]

[86]
Jia M, Wu C, Gao F, et al. Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain. Mol Pain  2017; 13.
 [http://dx.doi.org/10.1177/1744806917719804] [PMID: 28714351]

[87]
Kang L, Yayi H, Fang Z, Bo Z, Zhongyuan X. Dexmedetomidine attenuates P2X4 and NLRP3 expression in the spine of rats with diabetic neuropathic pain. Acta Cir Bras  2019; 34(11): e201901105.
 [http://dx.doi.org/10.1590/s0102-865020190110000005] [PMID: 31859818]

[88]
Sun Q, Wang C, Yan B, et al. Jinmaitong ameliorates diabetic peripheral neuropathy through suppressing TXNIP/NLRP3 inflammasome activation in the streptozotocin-induced diabetic rat model. Diabetes Metab Syndr Obes  2019; 12: 2145-55.
 [http://dx.doi.org/10.2147/DMSO.S223842] [PMID: 31802922]

[89]
Zheng T, Wang Q, Bian F, et al. Salidroside alleviates diabetic neuropathic pain through regulation of the AMPK-NLRP3 inflammasome axis. Toxicol Appl Pharmacol  2021; 416: 115468.
 [http://dx.doi.org/10.1016/j.taap.2021.115468] [PMID: 33639149]

[90]
Li DX, Wang CN, Wang Y, et al. NLRP3 inflammasome-dependent pyroptosis and apoptosis in hippocampus neurons mediates depressive-like behavior in diabetic mice. Behav Brain Res  2020; 391: 112684.
 [http://dx.doi.org/10.1016/j.bbr.2020.112684] [PMID: 32454054]

[91]
Cheng YC, Chu LW, Chen JY, et al. Loganin attenuates high glucose-induced schwann cells pyroptosis by inhibiting ROS generation and NLRP3 inflammasome activation. Cells  2020; 9(9): 1948.
 [http://dx.doi.org/10.3390/cells9091948] [PMID: 32842536]

[92]
Patel S, Srivastava S, Singh MR, Singh D. Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed Pharmacother  2019; 112: 108615.
 [http://dx.doi.org/10.1016/j.biopha.2019.108615] [PMID: 30784919]

[93]
Bevan D, Gherardi E, Fan TP, Edwards D, Warn R. Diverse and potent activities of HGF/SF in skin wound repair. J Pathol  2004; 203(3): 831-8.
 [http://dx.doi.org/10.1002/path.1578] [PMID: 15221943]

[94]
Barrientos S, Brem H, Stojadinovic O, Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen  2014; 22(5): 569-78.
 [http://dx.doi.org/10.1111/wrr.12205] [PMID: 24942811]

[95]
Kaur P, Choudhury D. Insulin promotes wound healing by inactivating NFkβP50/P65 and activating protein and lipid biosynthesis and alternating Pro/Anti-inflammatory cytokines dynamics. Biomol Concepts  2019; 10(1): 11-24.
 [http://dx.doi.org/10.1515/bmc-2019-0002] [PMID: 30827953]

[96]
Fei J, Ling YM, Zeng MJ, Zhang KW. Shixiang plaster, a traditional chinese medicine, promotes healing in a rat model of diabetic ulcer through the receptor for advanced glycation end products (RAGE)/Nuclear Factor kappa B (NF-κB) and Vascular Endothelial Growth Factor (VEGF)/Vascular Cell Adhesion Molecule-1 (VCAM-1)/Endothelial Nitric Oxide Synthase (eNOS) signaling pathways. Med Sci Monit  2019; 25: 9446-57.
 [http://dx.doi.org/10.12659/MSM.918268] [PMID: 31825949]

[97]
Cam ME, Ertas B, Alenezi H, et al. Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanofibrous scaffolds: An in vitro and in vivo evaluation study. Mater Sci Eng C  2021; 119: 111586.
 [http://dx.doi.org/10.1016/j.msec.2020.111586] [PMID: 33321632]

[98]
Yuan YF, Das SK, Li MQ, Vitamin D. Vitamin D ameliorates impaired wound healing in streptozotocin-induced diabetic mice by suppressing endoplasmic reticulum stress. J Diabetes Res  2018; 2018: 1-10.
 [http://dx.doi.org/10.1155/2018/1757925] [PMID: 29707582]

[99]
Mabood Khalil MA, Al-Ghamdi SMG, Dawood US, et al. Mammalian target of rapamycin inhibitors and wound healing complications in kidney transplantation: Old myths and new realities. J Transplant  2022; 2022: 1-28.
 [http://dx.doi.org/10.1155/2022/6255339] [PMID: 35265364]

[100]
Huang X, Sun J, Chen G, et al. Resveratrol promotes diabetic wound healing via SIRT1-FOXO1-c-Myc signaling pathway-mediated angiogenesis. Front Pharmacol  2019; 10: 421.
 [http://dx.doi.org/10.3389/fphar.2019.00421] [PMID: 31068817]

[101]
Wang X, Li W, Lu S, Ma Z. Modulation of the wound healing through noncoding RNA interplay and GSK-3β/NF-κB signaling interaction. Int J Genomics  2021; 2021: 1-11.
 [http://dx.doi.org/10.1155/2021/9709290] [PMID: 34485505]

[102]
Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes  2014; 63(3): 1103-14.
 [http://dx.doi.org/10.2337/db13-0927] [PMID: 24194505]

[103]
Weinheimer-Haus EM, Mirza RE, Koh TJ. Nod-like receptor protein-3 inflammasome plays an important role during early stages of wound healing. PLoS One  2015; 10(3): e0119106.
 [http://dx.doi.org/10.1371/journal.pone.0119106] [PMID: 25793779]

[104]
Dai J, Jiang C, Chen H, Chai Y. Rapamycin attenuates high glucose-induced inflammation through modulation of mTOR/NF-κB pathways in macrophages. Front Pharmacol  2019; 10: 1292.
 [http://dx.doi.org/10.3389/fphar.2019.01292] [PMID: 31736762]

[105]
Zhao Y, Wang Q, Yan S, et al. Bletilla striata polysaccharide promotes diabetic wound healing through inhibition of the NLRP3 inflammasome. Front Pharmacol  2021; 12: 659215.
 [http://dx.doi.org/10.3389/fphar.2021.659215] [PMID: 33981238]

[106]
Li X, Wang T, Tao Y, Wang X, Li L, Liu J. MF-094, a potent and selective USP30 inhibitor, accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome. Exp Cell Res  2022; 410(2): 112967.
 [http://dx.doi.org/10.1016/j.yexcr.2021.112967] [PMID: 34883112]

[107]
Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol  2019; 26(2_suppl): 25-32.
 [http://dx.doi.org/10.1177/2047487319878371] [PMID: 31722562]

[108]
Zhou Y, Little PJ, Downey L, et al. The role of toll-like receptors in atherothrombotic cardiovascular disease. ACS Pharmacol Transl Sci  2020; 3(3): 457-71.
 [http://dx.doi.org/10.1021/acsptsci.9b00100] [PMID: 32566912]

[109]
Yehualashet AS. Toll-like receptors as a potential drug target for diabetes Mellitus and diabetes-associated complications. Diabetes Metab Syndr Obes  2020; 13: 4763-77.
 [http://dx.doi.org/10.2147/DMSO.S274844] [PMID: 33311992]

[110]
Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling. Circ Heart Fail  2011; 4(4): 474-82.
 [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.959833] [PMID: 21558447]

[111]
Dong B, Qi D, Yang L, et al. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am J Physiol Heart Circ Physiol  2012; 303(6): H732-42.
 [http://dx.doi.org/10.1152/ajpheart.00948.2011] [PMID: 22842069]

[112]
Jha JC, Ho F, Dan C, Jandeleit-Dahm K. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clinical Science  2018; 132(16): 1811-36.
 [http://dx.doi.org/10.1042/CS20171459]

[113]
Senatus L, López-Díez R, Egaña-Gorroño L, et al. RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism. JCI Insight  2020; 5(13): e137289.
 [http://dx.doi.org/10.1172/jci.insight.137289] [PMID: 32641587]

[114]
Tiong YL, Ng KY, Koh RY, Ponnudurai G, Chye SM. Melatonin inhibits high glucose-induced ox-LDL/LDL expression and apoptosis in human umbilical endothelial cells. Horm Mol Biol Clin Investig  2020; 41(4): 20200009.
 [http://dx.doi.org/10.1515/hmbci-2020-0009] [PMID: 32598308]

[115]
Wamique M, Himanshu D, Ali W. Expression levels and genetic polymorphism of scavenger receptor class B Type 1 as a biomarker of type 2 diabetes mellitus. Sultan Qaboos Univ Med J  2022; 22(1): 117-22.
 [http://dx.doi.org/10.18295/squmj.4.2021.042] [PMID: 35299814]

[116]
Ishigaki Y, Katagiri H, Gao J, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation  2008; 118(1): 75-83.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.745174] [PMID: 18559699]

[117]
Kremastiotis G, Handa I, Jackson C, George S, Johnson J. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. Sci Rep  2021; 11(1): 23081.
 [http://dx.doi.org/10.1038/s41598-021-02508-4] [PMID: 34848763]

[118]
Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med  2010; 25(8): 853-8.
 [http://dx.doi.org/10.1007/s11606-010-1340-y] [PMID: 20405332]

[119]
Fangel MV, Nielsen PB, Kristensen JK, et al. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus. Circ Arrhythm Electrophysiol  2019; 12(5): e007030.
 [http://dx.doi.org/10.1161/CIRCEP.118.007030] [PMID: 30995869]

[120]
Frati G, Schirone L, Chimenti I, et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res  2017; 113(4): 378-88.
 [http://dx.doi.org/10.1093/cvr/cvx011] [PMID: 28395009]

[121]
Jubaidi FF, Zainalabidin S, Taib IS, Hamid ZA, Budin SB. the potential role of flavonoids in ameliorating diabetic cardiomyopathy via alleviation of cardiac oxidative stress, inflammation and apoptosis. Int J Mol Sci  2021; 22(10): 5094.
 [http://dx.doi.org/10.3390/ijms22105094] [PMID: 34065781]

[122]
Ren X, Zuo G, Wu W, et al. Atorvastatin alleviates experimental diabetic cardiomyopathy by regulating the GSK-3β-PP2Ac-NF-κB signaling axis. PLoS One  2016; 11(11): e0166740.
 [http://dx.doi.org/10.1371/journal.pone.0166740] [PMID: 27851811]

[123]
González-Moro A, Valencia I, Shamoon L, Sánchez-Ferrer CF, Peiró C, de la Cuesta F. NLRP3 inflammasome in vascular disease: A recurrent villain to combat pharmacologically. Antioxidants  2022; 11(2): 269.
 [http://dx.doi.org/10.3390/antiox11020269] [PMID: 35204152]

[124]
Luo B, Li B, Wang W, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One  2014; 9(8): e104771.
 [http://dx.doi.org/10.1371/journal.pone.0104771] [PMID: 25136835]

[125]
Monnerat G, Alarcón ML, Vasconcellos LR, et al. Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice. Nat Commun  2016; 7(1): 13344.
 [http://dx.doi.org/10.1038/ncomms13344] [PMID: 27882934]

[126]
Wang X, Pan J, Liu H, et al. AIM2 gene silencing attenuates diabetic cardiomyopathy in type 2 diabetic rat model. Life Sci  2019; 221: 249-58.
 [http://dx.doi.org/10.1016/j.lfs.2019.02.035] [PMID: 30790610]

[127]
Pfeiler S, Winkels H, Kelm M, Gerdes N. IL-1 family cytokines in cardiovascular disease. Cytokine  2019; 122: 154215.
 [http://dx.doi.org/10.1016/j.cyto.2017.11.009] [PMID: 29198612]

[128]
Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs  2015; 24(3): 283-307.
 [http://dx.doi.org/10.1517/13543784.2015.974804] [PMID: 25345753]

[129]
Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation  2019; 139(10): 1289-99.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038010] [PMID: 30586730]

[130]
Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care  2004; 27(3): 813-23.
 [http://dx.doi.org/10.2337/diacare.27.3.813] [PMID: 14988310]

[131]
de Lourdes Ochoa-González F, González-Curiel IE, Cervantes-Villagrana AR, Fernández-Ruiz JC, Castañeda-Delgado JE. Innate immunity alterations in type 2 diabetes mellitus: understanding infection susceptibility. Curr Mol Med  2021; 21(4): 318-31.
 [http://dx.doi.org/10.2174/1566524020999200831124534] [PMID: 32867637]

[132]
Wohlford GF, Van Tassell BW, Billingsley HE, et al. Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral nlrp3 inhibitor dapansutrile in subjects with NYHA II–III systolic heart failure. J Cardiovasc Pharmacol  2021; 77(1): 49-60.
 [http://dx.doi.org/10.1097/FJC.0000000000000931] [PMID: 33235030]

[133]
Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care  2016; 39(S2) (Suppl. 2): S244-52.
 [http://dx.doi.org/10.2337/dcS15-3015] [PMID: 27440839]

[134]
Deans KA, Sattar N. “Anti-inflammatory” drugs and their effects on type 2 diabetes. Diabetes Technol Ther  2006; 8(1): 18-27.
 [http://dx.doi.org/10.1089/dia.2006.8.18] [PMID: 16472047]

[135]
Yaribeygi H, Butler AE, Barreto GE, Sahebkar A. Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients. J Cell Physiol  2019; 234(3): 2436-46.
 [http://dx.doi.org/10.1002/jcp.27278] [PMID: 30191997]

[136]
Bellucci PN, González Bagnes MF, Di Girolamo G, González CD. Potential effects of nonsteroidal anti-inflammatory drugs in the prevention and treatment of type 2 diabetes mellitus. J Pharm Pract  2017; 30(5): 549-56.
 [http://dx.doi.org/10.1177/0897190016649551] [PMID: 27194069]

[137]
van Asseldonk EJP, Stienstra R, Koenen TB, Joosten LAB, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab  2011; 96(7): 2119-26.
 [http://dx.doi.org/10.1210/jc.2010-2992] [PMID: 21508140]

[138]
van Poppel PCM, van Asseldonk EJP, Holst JJ, Vilsbøll T, Netea MG, Tack CJ. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab  2014; 16(12): 1269-73.
 [http://dx.doi.org/10.1111/dom.12357] [PMID: 25039318]

[139]
Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab  2013; 39(6): 524-31.
 [http://dx.doi.org/10.1016/j.diabet.2013.07.003] [PMID: 24075453]
Rights & Permissions Print Cite
Article Metrics
34
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1566524023666220922114701	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666
Current Molecular Medicine

Role of Innate Immune and Inflammatory Responses in the Development of Secondary Diabetic Complications

Abstract

Related Journals

Related Books

Related Articles
